Hologic (NASDAQ:HOLX) Price Target Cut to $70.00 by Analysts at Citigroup

Hologic (NASDAQ:HOLX) had its target price cut by Citigroup from $80.00 to $70.00 in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a neutral rating on the medical equipment provider’s stock.

Several other brokerages have also weighed in on HOLX. Evercore ISI lowered their target price on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research note on Thursday, February 6th. Morgan Stanley lowered their price objective on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Leerink Partnrs cut shares of Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Finally, Needham & Company LLC cut shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price on the stock. in a report on Monday, February 3rd. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $84.62.

Hologic Stock Performance

NASDAQ:HOLX opened at $62.30 on Tuesday. The company has a fifty day moving average of $68.77 and a two-hundred day moving average of $75.64. The stock has a market capitalization of $13.98 billion, a PE ratio of 19.65, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic has a fifty-two week low of $62.28 and a fifty-two week high of $84.67.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, research analysts forecast that Hologic will post 4.28 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Hologic

A number of hedge funds have recently modified their holdings of the business. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Hologic in the 4th quarter valued at $28,269,000. Jefferies Financial Group Inc. boosted its position in shares of Hologic by 141.5% during the 4th quarter. Jefferies Financial Group Inc. now owns 96,849 shares of the medical equipment provider’s stock worth $6,982,000 after purchasing an additional 56,742 shares in the last quarter. Forum Financial Management LP purchased a new stake in shares of Hologic during the 4th quarter worth $324,000. Toronto Dominion Bank boosted its position in shares of Hologic by 7.9% during the 4th quarter. Toronto Dominion Bank now owns 124,308 shares of the medical equipment provider’s stock worth $8,961,000 after purchasing an additional 9,076 shares in the last quarter. Finally, North Star Asset Management Inc. boosted its position in shares of Hologic by 0.3% during the 4th quarter. North Star Asset Management Inc. now owns 252,857 shares of the medical equipment provider’s stock worth $18,228,000 after purchasing an additional 687 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.